No Data
No Data
Medicenna Therapeutics Announces Closing of CA$20 Million Investment From RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" o
Canadian Investment Regulatory Organization Trading Halt - MDNA
Medicenna Therapeutics Announces CA$20 Million Investment From RA Capital Management
Medicenna Therapeutics Up 13% After Flagging Presentations
Medicenna Therapeutics (MDNA.TO) was up near 13% on Wednesday after saying it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of
Medicenna Announces Oral Presentation of MDNA11 Data From the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Oral presentation of MDNA11's Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today
Medicenna Therapeutics (MDNA.TO), a clinical-stage immunotherapy company focused on the development of Superkines that saw its shares drop near 12% today, after trade Tuesday said it presented updated